IL-18 Production Downstream of the Nlrp3 Inflammasome Confers Protection against Colorectal Tumor Formation
Open accessThe DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
Colorectal cancer is a leading cause of cancer-related deaths worldwide. Chronic inflammation is recognized as a predisposing factor for the development of colon cancer, but the molecular mechanisms linking inflammation and tumorigenesis have remained elusive. Recent studies revealed a crucial role for the NOD-like receptor protein Nlrp3 in regulating inflammation through the assembly of proinflammatory protein complexes termed inflammasomes. However, its role in colorectal tumor formation remains unclear. In this study, we showed that mice deficient for Nlrp3 or the inflammasome effector caspase-1 were highly susceptible to azoxymethane/dextran sodium sulfate-induced inflammation and suffered from dramatically increased tumor burdens in the colon. This was a consequence of markedly reduced IL-18 levels in mice lacking components of the Nlrp3 inflammasome, which led to impaired production and activation of the tumor suppressors IFN-γ and STAT1, respectively. Thus, IL-18 production downstream of the Nlrp3 inflammasome is critically involved in protection against colorectal tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple studies using different mice deficient for inflammasomes components (including NLRP3, NLRP1, NLRP6, NLRC4 and Caspase-1) found that the inflammasomes protect mice from colitis-associated CRC [120,121,122,123,124].”
From Gut Microbiota and Cancer: From Pathogenesis to Therapy (2019) · cites this paper as [124]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Commensal bacteria and their bioproducts induce inflammasomes activation and IL-18 production in the gut, which, in turn, prevents intestinal barrier disruption and dysbiosis [121,124,131,132,133].”
From Gut Microbiota and Cancer: From Pathogenesis to Therapy (2019) · cites this paper as [124]
Experimental — accuracy not yet measuredIn the citing paper
“In fact, IL-18 KO or IL-18R KO mice are also highly sensitive to colitis-associated CRC [124,125].”
From Gut Microbiota and Cancer: From Pathogenesis to Therapy (2019) · cites this paper as [124]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755 · cited 1×
“The synthesis and secretion of these cytokines is controlled by transcription factors of the STAT, NF-kB, and AP-1 families (6).”
BackgroundDarnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080
Martinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
Hugot, J.-P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J.-P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C. A., Gassull, M., et al. (2001) · Nature · doi:10.1038/35079107 · Cited by 5,591 · cited 1×
“in the NLR protein NOD2 are linked with the development of Crohn’s disease in humans (41, 42).”
BackgroundA frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R. H., et al. (2001) · Nature · doi:10.1038/35079114 · Cited by 5,030 · cited 1×
“in the NLR protein NOD2 are linked with the development of Crohn’s disease in humans (41, 42).”
BackgroundNuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519
The risk of colorectal cancer in ulcerative colitis: a meta-analysis
Eaden, J. A., Abrams, K. R., & Mayberry, J. F. (2001) · Gut · doi:10.1136/gut.48.4.526 · Cited by 2,959
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896 · cited 1×
“Indeed, IL-18 was originally identified as the “IFN-g–inducing factor” (22), and IFN-g has been described as a pleiotropic cytokine with potent antitumor activity (34, 37).”
BackgroundCELLULAR RESPONSES TO INTERFERON-γ
Boehm, U., Klamp, T., Groot, M., & Howard, J. C. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.749 · Cited by 2,890
Cited by
Items 101–200 of 457
de Almeida, V. M., Galvão, I., & Vieira, A. T. (2019) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2019.0011 · Cited by 120
ENaC-mediated sodium influx exacerbates NLRP3-dependent inflammation in cystic fibrosis
Scambler, T., Jarosz-Griffiths, H., Reyna, S. J. L., Pathak, S., Wong, C., Holbrook, J. A., Martinon, F., Savic, S., Peckham, D. G., & McDermott, M. (2019) · eLife · doi:10.7554/elife.49248 · Cited by 117
“Furthermore, IL-18 has an epithelial protective role in promoting repair of gut epithelium (Zaki et al., 2010), and more ex vivo studies and CF disease models are required to elucidate the benefits or hazards of IL-18 blockade.”
BackgroundNOD‐like receptor C4 Inflammasome Regulates the Growth of Colon Cancer Liver Metastasis in NAFLD
Ohashi, K., Wang, Z., Yang, Y. M., Billet, S., Tu, W., Pimienta, M., Cassel, S. L., Pandol, S. J., Lu, S. C.-L., Sutterwala, F. S., et al. (2019) · Hepatology · doi:10.1002/hep.30693 · Cited by 115
“Previous studies demonstrated that mice lacking NLRP3 were more susceptible to experimental colitis and colitis-associated CRC models, and that NLRP3-/- mice had increased CRC liver metastases.(46-49) NLRP3-dependent IL-18 activation was shown to stimulate NK cells, which enhanced their tumoricidal activity against CR…”
BackgroundDubey, S. R., Turnbull, C., Pandey, A., Zhao, A., Kurera, M., Al-Zidan, R. N., Shen, C. X., Gautam, M., Mahajan, S., Jadhav, P. S., et al. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01354-y · Cited by 115
Karki, R., Malireddi, R. K. S., Zhu, Q., & Kanneganti, T. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1317414 · Cited by 109
“NLRC3 does not regulate inflammasome activation Certain members of the NLR family can form inflammasome complexes.19 Inflammasome-mediated caspase-1 activation during dextran sulfate sodium (DSS)–induced colitis is protective against colitis and colitis-associated tumorigenesis, particularly through the production of…”
BackgroundSelf-citationIntegrative inflammasome activity in the regulation of intestinal mucosal immune responses
Elinav, E., Henao‐Mejia, J., & Flavell, R. A. (2012) · Mucosal Immunology · doi:10.1038/mi.2012.115 · Cited by 107
“The increased tumorigenesis in Nlrp6-deficient mice was associated with elevated inflammatory responses and defective production of IL-18 within the colon.73 Furthermore, gene expression analysis of tumors from Nlrp6 mice showed alterations in pathways involved in epithelial proliferation and transformation (mainly of…”
BackgroundInfluentialThe emerging roles of inflammasome‐dependent cytokines in cancer development
Gorp, H. V., & Lamkanfi, M. (2019) · EMBO Reports · doi:10.15252/embr.201847575 · Cited by 104
Self-citationRenal macrophages and NLRP3 inflammasomes in kidney diseases and therapeutics
Islamuddin, M., & Qin, X. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01996-3 · Cited by 104
“Ongoing human trials are investigating VX-765 in conditions like psoriasis and treatment-resistant partial epilepsy [249, 250].”
BackgroundInflammasome signaling in colorectal cancer
Sharma, B. R., & Kanneganti, T. (2022) · Translational research · doi:10.1016/j.trsl.2022.09.002 · Cited by 103
Self-citationSpecific inflammasomes in complex diseases
Masters, S. L. (2012) · Clinical Immunology · doi:10.1016/j.clim.2012.12.006 · Cited by 102
Non-Inflammasome Forming NLRs in Inflammation and Tumorigenesis
Allen, I. C. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00169 · Cited by 103
Regulation of adaptive immunity by the NLRP3 inflammasome
Chen, M., Wang, H., Chen, W., & Meng, G. (2010) · International Immunopharmacology · doi:10.1016/j.intimp.2010.11.025 · Cited by 100
“cells (IEC) or immune cells, respectively [37–42].”
Targeting the NLRP3 Inflammasome as a New Therapeutic Option for Overcoming Cancer
Missiroli, S., Perrone, M., Boncompagni, C., Borghi, C., Campagnaro, A., Marchetti, F., Anania, G., Greco, P., Fiorica, F., Pinton, P., et al. (2021) · Cancers · doi:10.3390/cancers13102297 · Cited by 97
Pyroptosis in Cancer: Friend or Foe?
Lu, X., Guo, T., & Zhang, X. (2021) · Cancers · doi:10.3390/cancers13143620 · Cited by 92
“Moreover, as mentioned before, IL-18 has both pro [41–43] and antitumorigenic effects [52,53].”
BackgroundRole of Nlrp6 and Nlrp12 in the maintenance of intestinal homeostasis
Chen, G. (2014) · European Journal of Immunology · doi:10.1002/eji.201344135 · Cited by 92
Cell death–mediated cytokine release and its therapeutic implications
Place, D. E., & Kanneganti, T.-D. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181892 · Cited by 84
“Blockade of IL-18 may be beneficial in the context of colitis, inflammatory bowel disease, or cardiac disease, but conflicting findings on harmful and beneficial roles for IL-18 require more study (Zaki et al., 2010; Dinarello et al., 2013; Kanai et al., 2013; Toldo et al., 2014).”
BackgroundSelf-citationGatault, S., Delbeke, M., Driss, V., Sarazin, A., Dendooven, A., Kahn, J., Lefèvre, G., & Capron, M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402914 · Cited by 88
“Tumors were observed significantly more frequently in colons of il-18 mice than in colons of wildtype mice (26, 27).”
BackgroundBeyond IgE: Alternative Mast Cell Activation Across Different Disease States
Lyons, D. O., & Pullen, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041498 · Cited by 88
“This connection between NLRP3, bowel diseases, and cancer is multifaceted and the resulting inflammation and cytokine secretion (namely IL-18) can be protective against tumor growth [65].”
BackgroundBouhamida, E., Morciano, G., Perrone, M., Kahsay, A. E., Della Sala, M., Wieckowski, M. R., Fiorica, F., Pinton, P., Giorgi, C., & Patergnani, S. (2022) · Biology · doi:10.3390/biology11020300 · Cited by 87
Divergent functions of NLRP3 inflammasomes in cancer: a review
Shadab, A., Mahjoor, M., Abbasi‐Kolli, M., Afkhami, H., Moeinian, P., & Safdarian, A.-R. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01235-9 · Cited by 87
“NLRP3-dependent IL-18 production inhibits neoplastic events, potentially by inducing IFN-γ production and STAT1 signaling [136].”
BackgroundInflammasome inhibitors: promising therapeutic approaches against cancer
Xu, S., Li, X., Liu, Y., Xia, Y., Chang, R., & Zhang, C. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0755-0 · Cited by 86
Involvement of inflammasomes in tumor microenvironment and tumor therapies
Zhang, Z., Li, X., Wang, Y., Wei, Y., & Wei, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01407-7 · Cited by 88
“Similarly, NLRP3-deficient mice are susceptible to colitis-associated cancer [137].”
BackgroundLi, P., Chen, G., Zhang, J., Pei, C., Chen, Y., Gong, J., Deng, S., Cai, K., Li, H., Wang, D., et al. (2022) · Food & Function · doi:10.1039/d1fo03360c · Cited by 85
The machinery of Nod‐like receptors: refining the paths to immunity and cell death
Saleh, M. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01045.x · Cited by 71
Emerging Significance of NLRs in Inflammatory Bowel Disease
Davis, B. K., Philipson, C., Hontecillas, R., Eden, K., Bassaganya-Riera, J., & Allen, I. C. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000151 · Cited by 67
Beneficial and Detrimental Roles of NLRs in Carcinogenesis
Janowski, A. M., Kolb, R. H., Zhang, W., & Sutterwala, F. S. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00370 · Cited by 84
“Treatment of caspase-1−/− mice with recombinant IL-18 led to a reduction in disease demonstrating a crucial role of IL-18 in protection against CAC development (14).”
BackgroundA comprehensive guide to studying inflammasome activation and cell death
Tweedell, R. E., Malireddi, R. K. S., & Kanneganti, T. (2020) · Nature Protocols · doi:10.1038/s41596-020-0374-9 · Cited by 82
Self-citationNLRP3 promotes inflammation‐induced skin cancer but is dispensable for asbestos‐induced mesothelioma
Chow, M. T., Tschopp, J., Möller, A., & Smyth, M. J. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2012.46 · Cited by 74
NOD-like receptors in intestinal homeostasis and epithelial tissue repair
Parlato, M., & Yeretssian, G. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15069594 · Cited by 79
“Equally, lack of epithelial IL-18 expression in NLRP3 deficient mice enhanced susceptibility of these mice to DSS-induced colitis when compared to control wild-type mice [265,267,268].”
BackgroundDifferential role of the NLRP 3 inflammasome in infection and tumorigenesis
Tartey, S., & Kanneganti, T. (2019) · Immunology · doi:10.1111/imm.13046 · Cited by 77
Self-citationNLRPs, microbiota, and gut homeostasis: unravelling the connection
Zambetti, L. P., & Mortellaro, A. (2014) · The Journal of Pathology · doi:10.1002/path.4357 · Cited by 69
“A similar increase in tumour burden was observed in the colons of AOM/DSS-treated Il18−/− and Il18r1−/− mice [39,42], further illustrating its importance during colitis-associated CRC development in this model.”
BackgroundInfluentialTang, Z., Ji, L., Han, M., Xie, J., Zhong, F., Zhang, X., Su, Q., Yang, Z., Liu, Z., Gao, H., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118065 · Cited by 74
Błażejewski, A. J., Thiemann, S., Schenk, A., Pils, M. C., Gálvez, E. J. C., Roy, U., Heise, U., de Zoete, M. R., Flavell, R. A., & Strowig, T. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.058 · Cited by 75
NLRP3 inflammasome in health and disease (Review)
Wang, H., Ma, L., Su, W., Liu, Y., Xie, N., & Liu, J. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5489 · Cited by 76
Licensing Adaptive Immunity by NOD-Like Receptors
Liu, D., Rhebergen, A. M., & Eisenbarth, S. C. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00486 · Cited by 72
“immunity, one study showed that in the absence of NLRP3 and caspase-1, reduced IL-18 in a colorectal tumor model led to diminished IFN-γ levels in the colon (214).”
BackgroundThe contrasting roles of inflammasomes in cancer.
He, Q., Fu, Y., Tian, D., & Yan, W. (2018) · Europe PMC (PubMed Central) · Cited by 73
Th1 cytokine-based immunotherapy for cancer
Xu, H. (2014) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(14)60305-2 · Cited by 71
(2022) · doi:10.1016/j.hsr.2021.100010 · Cited by 69
Inflammasome as a promising therapeutic target for cancer
Lee, C., Do, H. T. T., Her, J., Kim, Y., Seo, D., & Rhee, I. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116593 · Cited by 69
Savic, S., Dickie, L. J., Wittmann, M., & McDermott, M. (2012) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2012.07.009 · Cited by 70
ASC-associated inflammation promotes cecal tumorigenesis in aryl hydrocarbon receptor-deficient mice
Ikuta, T., Kobayashi, Y., Kitazawa, M., Shiizaki, K., Itano, N., Noda, T., Pettersson, S., Poellinger, L., Fujii-Kuriyama, Y., Taniguchi, S., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt083 · Cited by 63
Dabkeviciene, D., Jonusiene, V., Zitkute, V., Zalyte, E., Grigaitis, P., Kirveliene, V., & Sasnauskiene, A. (2015) · Medical Oncology · doi:10.1007/s12032-015-0703-y · Cited by 55
“The blockage of CXCR2 resulted in a decreased expression of tumor growth promoting cytokines, including IL-7 [21] and EGF [22], as well as an increased expression of cancerogenesis-preventing cytokines IL-18 [23] and CCL25 [24].”
BackgroundInflammation and Prostate Cancer
Tewari, A. K., Stockert, J. A., Yadav, S. S., Yadav, K. K., & Khan, I. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-95693-0_3 · Cited by 68
Raut, P. K., Kim, S., Choi, D. Y., Jeong, G., & Park, P. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.01.006 · Cited by 68
Nod-like receptors in intestinal homeostasis, inflammation, and cancer
Werts, C., Rubino, S. J., Ling, A., Girardin, S. E., & Philpott, D. J. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0411183 · Cited by 67
“The protective phenotype of the NLRP3 inflammasome is linked to the production of IL-18, as lower levels of IL-18 secretion were measured in colonic cells isolated from NLRP3 / , ASC / , and caspase-1 / mice [26] or in the serum of ASC / and caspase-1 / mice [28].”
BackgroundInfluentialAguilera, M., Darby, T. M., & Melgar, S. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.04.003 · Cited by 67
Licandro, G., Ling Khor, H., Beretta, O., Lai, J., Derks, H., Laudisi, F., Conforti‐Andreoni, C., Liang Qian, H., Gee Teng, G., Ricciardi‐Castagnoli, P., et al. (2013) · European Journal of Immunology · doi:10.1002/eji.201242918 · Cited by 62
NLRP3 inflammasome in colitis and colitis-associated colorectal cancer
Perera, A. P., Sajnani, K., Dickinson, J. L., Eri, R. D., & Körner, H. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9783-2 · Cited by 64
The IL-1 family in tumorigenesis and antitumor immunity
Sun, R., Gao, D. S., Shoush, J., & Lu, B. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.002 · Cited by 63
Melatonin and Cancer: A Polyhedral Network Where the Source Matters
Bonmatí‐Carrión, M., & Tomás‐Loba, A. (2021) · Antioxidants · doi:10.3390/antiox10020210 · Cited by 63
NLRP3 inflammasomes that induce antitumor immunity
Zhivaki, D., & Kagan, J. C. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.05.001 · Cited by 63
Wang, Y., Wang, H., Qian, C., Tang, J., Zhou, W., Liu, X., You, Q., & Hu, R. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.11.015 · Cited by 62
Pyroptosis in cancer therapy: a double-edged sword for immune activation and tumor progression
Alishvandi, A., Aram, C., Shahrivar, F. F., Kesharwani, P., & Sahebkar, A. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02506-4 · Cited by 63
“IL-18 deficiency due to NLRP3 loss can impair IFN-γ production as well as STAT1 activation, thereby increasing tumor burdens in CRC [343].”
Correlation Between the NLRP3 Inflammasome and the Prognosis of Patients With LSCC
Yi, X., Du, H.-D., Tang, D., Zhang, D., Zhou, J., Zhai, C., Yuan, C., Hsueh, C., Li, S., Heng, Y., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00588 · Cited by 59
“(27) demonstrated that the NLRP3 inflammasome prevented the development of inflammation-associated colorectal tumorigenesis.”
BackgroundInflammasomes: Emerging Central Players in Cancer Immunology and Immunotherapy
Karan, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03028 · Cited by 58
Wang, Z., Zeng, F., Hu, Y., Wang, X., Zhao, F., Zhou, P., Hu, J., Xiao, Y., Hu, Z., Guo, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00820-z · Cited by 57
“Our findings highlight the role of IL-37 in harnessing antitumor immunity by inactivation of cytotoxic T cells and establish a new defined inhibitory factor IL-37/SIGIRR in cancerimmunity cycle as therapeutic targets in CRC. Signal Transduction and Targeted Therapy (2022) 7:19 ; https://doi.org/10.1038/s41392-021-0082…”
BackgroundInfluentialNew insights into the non-enzymatic function of HDAC6
Zhu, Y.-Z., Feng, M., Wang, B., Zheng, Y., Jiang, D., Zhao, L., Mamun, M., Kang, H., Nie, H., Zhang, X., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114438 · Cited by 56
Inflammasome in Intestinal Inflammation and Cancer
Nunes, T., & de Souza, H. S. P. (2013) · Mediators of Inflammation · doi:10.1155/2013/654963 · Cited by 56
“Mice lacking NLRP3 were shown to be more susceptible to tumorigenesis in the AOM-DSS model in some studies [7, 9], but not in others [10].”
BackgroundMethodResultInfluentialNLRP3 Inflammasome Promotes the Progression of Acute Myeloid Leukemia via IL-1β Pathway
Zhong, C., Wang, R., Hua, M., Zhang, C., Han, F., Xu, M., Yang, X., Li, G., Hu, X., Sun, T., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661939 · Cited by 56
“Though the inflammasome activation and IL-18 signaling pathways are largely beneficial in colitis-associated colorectal cancer (32, 36), it has been widely accepted that inflammasome can promote the development of many malignant tumors, including head and neck squamous cell carcinoma, fibrosarcoma, melanoma, gastric c…”
BackgroundInflammasomes: Caspase-1-Activating Platforms with Critical Roles in Host Defense
Vande Walle, L., & Lamkanfi, M. (2011) · Frontiers in Microbiology. · doi:10.3389/fmicb.2011.00003 · Cited by 50
“…and later renamed caspase-1, has been linked to inflammatory bowel diseases (Villani et al., 2009; Allen et al., 2010; Dupaul-Chicoine et al., 2010; Zaki et al., 2010a,b), gouty arthritis (Martinon et al., 2006), type II diabetes (Larsen et al., 2007), and less common autoinflammatory disorders…”
BackgroundSelf-citationXu, L., Zhu, J., Rong, L., Yang, H., Wang, B., Lü, S., Zhang, L. L., Li, F., Yang, S., Wang, Z., et al. (2024) · Theranostics · doi:10.7150/thno.95423 · Cited by 55
“These may be associated with IL-18, which is regulated by NLRP3, can activate NF-κB, and then impact the level of interferon-related gene STAT1 [26, 27].”
BackgroundErasha, A. M., El-Gendy, H. F., Aly, A. S., Fernández‐Ortiz, M., & Sayed, R. K. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062716 · Cited by 54
“ABHD5 plays a crucial role in lipid metabolism, and its absence has been found to enhance macrophage reprogramming and inflammasome activation, further highlighting the connection between metabolic alterations in the TME and inflammasome activation [251].”
NLRP3 inflammasome-induced pyroptosis in digestive system tumors
Wen, J., Xuan, B., Liu, Y., Wang, L., He, L., Meng, X., Zhou, T., & Wang, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1074606 · Cited by 53
“Thus, the NLRP3 inflammasome is considered instrumental in resistance to colitis-associated tumorigenesis (128, 129).”
BackgroundSTAT3 targeting by polyphenols: Novel therapeutic strategy for melanoma
Momtaz, S., Niaz, K., Maqbool, F., Abdollahi, M. R., Rastrelli, L., & Nabavi, S. M. (2016) · BioFactors · doi:10.1002/biof.1345 · Cited by 53
“It has been documented that resveratrol inhibits both STAT3 activity and STAT3 acetylation [87,244,249].”
BackgroundInflammasomes in Colitis and Colorectal Cancer: Mechanism of Action and Therapies.
Pandey, A., Shen, C. X., & Man, S. M. (2019) · Europe PMC (PubMed Central) · Cited by 53
Tumor-intrinsic determinants of immunogenic cell death modalities
Workenhe, S. T., Pol, J. G., & Kroemer, G. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1893466 · Cited by 53
Salmonella and the Inflammasome: Battle for Intracellular Dominance
Crowley, S. M., Knodler, L. A., & Vallance, B. A. (2016) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-41171-2_3 · Cited by 52
Tumor-Associated Inflammation: The Tumor-Promoting Immunity in the Early Stages of Tumorigenesis
Bi, Q., Wu, J., Qiu, X., Zhang, J., Sun, Z., & Wang, W. (2022) · Journal of Immunology Research · doi:10.1155/2022/3128933 · Cited by 52
“However, in contrast, deleting the Aim2 [129], Asc [129, 130], Nlrp3 [131, 132], Nlrc4 [133], Casp1 [132, 133], or Il-18r [134] genes invariably exacerbated the burden of AOM/DSS-induced colorectal cancer in mice.”
Inflammatory cell death in intestinal pathologies
Sharma, D., & Kanneganti, T. (2017) · Immunological Reviews · doi:10.1111/imr.12602 · Cited by 51
Self-citationSamoilă, I., Dinescu, S., & Costache, M. (2020) · Cells · doi:10.3390/cells9071647 · Cited by 51
“On the other hand, the second and more recently postulated theory, demonstrated that Cas-1−/− mice had an even more aggravated colitis, probably due to the insufficiency of IL-18, which is an early trigger of tissue repair [21,22].”
BackgroundSpecific NLRP3 inflammasome inhibitors: promising therapeutic agents for inflammatory diseases
Vong, C. T., Tseng, H. H. L., Yao, P., Yu, H., Wang, S., Zhong, Z., & Wang, Y. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.02.018 · Cited by 51
Therapeutic implications of inflammasome in inflammatory bowel disease
Khatri, V., & Kalyanasundaram, R. (2021) · The FASEB Journal · doi:10.1096/fj.202002622r · Cited by 51
Scarpitta, A., Hacker, U. T., Büning, H., Boyer, O., & Adriouch, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.731598 · Cited by 51
Interleukin 1β—A Potential Salivary Biomarker for Cancer Progression?
Idris, A., Ghazali, N. B., & Koh, D. S. Q. (2015) · Biomarkers in Cancer · doi:10.4137/bic.s25375 · Cited by 50
Identification and validation of a pyroptosis-related prognostic signature for thyroid cancer
Wu, P., Shi, J., Sun, W., & Zhang, H. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02231-0 · Cited by 48
Paudel, D., Nair, D. V. T., Tian, S., Hao, F., Goand, U. K., Joseph, G., Prodes, E., Chai, Z., Robert, C. E. M., Chassaing, B., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2341457 · Cited by 48
“48 Studies using knockout mouse models and exogenous recombinant IL-18 (rIL-18) administration have shown both protective 21,49 and detrimental 24 effects of IL-18 on colitis.”
Oroxylin A inhibits colitis by inactivating NLRP3 inflammasome
Zhou, W., Liu, X., Zhang, X., Tang, J., Li, Z., Wang, Q., & Hu, R. (2017) · Oncotarget · doi:10.18632/oncotarget.19440 · Cited by 48
“These processes are ascribed to the decreased production of NLRP3-mediated IL-18 which promotes enterocyte proliferation to repair damaged epithelial cells and maintain intestinal homeostasis [23, 24].”
Role of mTORC1 in intestinal epithelial repair and tumorigenesis
Kaur, H., & Moreau, R. F. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03085-6 · Cited by 49
The role of NLRP3 inflammasome in colorectal cancer: potential therapeutic target
Vafaei, S., Taheri, H., Hajimomeni, Y., Yaseri, A. F., & Zadeh, F. A. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02861-4 · Cited by 47
“As a result, IL-18 signaling downstream of the NLRP3 inflammasome is critical in the prevention of CRC development [49].”
BackgroundThe inflammasome: an emerging therapeutic oncotarget for cancer prevention
Zhiyu, W., Wang, N., Wang, Q., Peng, C. Y., Zhang, J., Liu, P., Ou, A., Zhong, S., Cordero, M. D., & Lin, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.9391 · Cited by 47
“Of note, IL-18 knockout mice generated more tumors than controls after administering AOM-DSS (azoxymethane- dextran sodium sulfate), whereas injection of recombinant IL-18 successfully restrained disease progression, which might be associated with MyD88-related pathway [104].”
BackgroundThe multifaceted roles of inflammasome proteins in cancer
Pétrilli, V. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000346 · Cited by 47
The role of cholesterol and mitochondrial bioenergetics in activation of the inflammasome in IBD
Astorga, J., Gasaly, N., Dubois‐Camacho, K., la Fuente, M. D., Landskron, G., Faber, K. N., Urra, F. A., & Hermoso, M. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1028953 · Cited by 46
“In data analysis on the Oncomine ® platform from patients with CRC, a decreased expression of in fl ammasome NLRP1, NLRP3, NLRC4 , and AIM2 was observed compared to healthy controls (114).”
BackgroundInfluentialNLRP6 in infection and inflammation
Anand, P. K., & Kanneganti, T. (2013) · Microbes and Infection · doi:10.1016/j.micinf.2013.06.009 · Cited by 47
“Apparently, this can be explained by the fact that IL-18 protects against intestinal damage by maintaining epithelial barrier integrity [40, 41].”
BackgroundSelf-citationThe inflammasome NLRP3 plays a protective role against a viral immunopathological lesion
Giménez, F., Bhela, S., Dogra, P., Harvey, M. L., Varanasi, S. K., Jaggi, U., & Rouse, B. T. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3hi0715-321r · Cited by 47
“In colitis, the absence of NLRP3 reduced the levels of IL-18, which was shown to be critically involved in the maintenance of intestinal homeostasis [50].”
BackgroundDNA-sensing inflammasomes: regulation of bacterial host defense and the gut microbiota
Man, S. M., Karki, R., & Kanneganti, T. (2016) · Pathogens and Disease · doi:10.1093/femspd/ftw028 · Cited by 46
“NLRP3 is required for mediating protection against chemically-induced colitis in mice (Allen et al. 2010; Zaki et al. 2010a,b; Hirota et al. 2011).”
BackgroundSelf-citationSubramaniam, R., Mizoguchi, A., & Mizoguchi, E. (2016) · Cancer Research Frontiers · doi:10.17980/2016.1 · Cited by 46
“There is a number of evidence to support that IL-18 is essential to protect from CAC, however there are also reports refuting this that indicate IL-18 promotes CAC: It is likely that higher concentrations of IL-18 promote tumorigenesis and optimum concentration of IL-18 prevents tumorigenesis (48-51).”
Pepelyayeva, Y., Rastall, D. P. W., Aldhamen, Y. A., O’Connell, P. M., Raehtz, S., Alyaqoub, F. S., Blake, M. K., Raedy, A. M., Angarita, A. M., Abbas, A. M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-30159-5 · Cited by 45
The Role of Inflammation and Inflammasome in Myeloproliferative Disease
Longhitano, L., Volti, G. L., Giallongo, C., Spampinato, M., Barbagallo, I. A., Rosa, M. D., Romano, A., Avola, R., Tibullo, D., & Palumbo, G. A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082334 · Cited by 45
Huang, L., Duan, S., Shao, H., Zhang, A., Chen, S., Zhang, P., Wang, N., Wang, W., Wu, Y., Wang, J., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-0983-4 · Cited by 44
Nod1 Limits Colitis-Associated Tumorigenesis by Regulating IFN-γ Production
Zhan, Y., Seregin, S. S., Chen, J., & Chen, G. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501822 · Cited by 44
“Indeed, Nlrp32/2 mice had significantly reduced levels of IFN-g within the colon tissue after AOM/DSS treatment similarly to that observed with Nod12/2 mice in the present study, and, additionally, the reduced IFN-g production was associated with decreased activation of STAT1 in mice deficient in caspase-1, which is d…”
InfluentialHradická, P., Beal, J., Kassayová, M., Foey, A., & Demečková, V. (2020) · Microorganisms · doi:10.3390/microorganisms8030387 · Cited by 43
“Better tumour surveillance of probiotic-fed DMH rats can be also linked to this probiotic potential to induce IL-18 secretion, as IL-18 is critically involved in protection against colorectal tumorigenesis [67].”
BackgroundNLR-regulated pathways in cancer: opportunities and obstacles for therapeutic interventions
Sharma, N., & Jha, S. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2123-8 · Cited by 44
“Macrophages release various tumorigenic factors in the tumor microenvironment, this is reflected in the significantly higher expression of COX-2 mRNA in colon tissue of Nlrp3 and Casp1 mice [40].”
BackgroundInflammation in sporadic colorectal cancer.
Moossavi, S., & Bishehsari, F. (2012) · PubMed · Cited by 44
Microbial metabolites are involved in tumorigenesis and development by regulating immune responses
Liu, J., Tian, R., Sun, C., Guo, Y., Dong, L., Li, Y., & Song, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1290414 · Cited by 41
NLRP3 inflammasome in digestive diseases: From mechanism to therapy
Qiang, R., Li, Y., Dai, X.-C., & Lv, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.978190 · Cited by 40
Kariagina, A., & Doseff, A. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415753 · Cited by 39
“Furthermore, injections of IL-18 into NLRP3-deficient mice to compensate for the inflammasome’s absence led to a lower number of primary tumors [147].”
BackgroundEpigenetic regulation of ASC/TMS1 expression: potential role in apoptosis and inflammasome function
Salminen, A., Kauppinen, A., Hiltunen, M. O., & Kaarniranta, K. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1524-9 · Cited by 39
Regulation of the gut microbiome by inflammasomes
Chen, G. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.11.011 · Cited by 38
“Similarly, susceptibility to colitis associated tumorigenesis using the (azoxymethane) AOM/DSS model in which mice are administered the carcinogen AOM followed by multiple rounds of colitis-inducing DSS, was also increased [12,25,30,31,35,36,39,40].”
He, L., Chen, Y., Wu, Y., Xu, Y. J., Zhang, Z., & Liu, Z. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2477-1 · Cited by 39
Src-family kinase-Cbl axis negatively regulates NLRP3 inflammasome activation
Chung, I., Yuan, S.-N., OuYang, C., Lin, H., Huang, K., Chen, Y.-J., Chung, A., Chu, C., Ojcius, D. M., Chang, Y., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1163-z · Cited by 38
Metadata
- Authors
- Zaki, M. H., Vogel, P., Body-Malapel, M., Lamkanfi, M., & Kanneganti, T.-D.
- Affiliations
- Department of Immunology , Memphis, TN 38105
- St. Jude Children's Research Hospital (US)
- Department of Physiopathology of Inflammatory Bowel Diseases, INSERM Unité 995 , Lille ,
- Vlaams Instituut voor Biotechnologie (BE)
- Corresponding author
- Kanneganti, Thirumala-Devi
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-10
- Volume
- 185
- Issue
- 8
- Pages
- 4912-4920
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- PMC
- PMC3104023
- OpenAlex
- W1954263225
- Cited by
- 411
- References
- 62
- Citations by year
- 2026: 16 · 2025: 18 · 2024: 39 · 2023: 26 · 2022: 42 · 2021: 43 · 2020: 20 · 2019: 30 · 2018: 26 · 2017: 24 · 2016: 22 · 2015: 26 · 2014: 18 · 2013: 25 · 2012: 20
- FWCI
- 7.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Funders
- Yale University
- St. Jude Children's Research Hospital
- American Lebanese Syrian Associated Charities (AR056296, CA 21765)
- Vlaamse regering
- National Institutes of Health (CA21765))
- Takeda Oncology
- National Cancer Institute (2 P30 CA21765, P30CA021765)
- National Institute of Allergy and Infectious Diseases (AI088177, R21AI088177)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR056296, AR-056296)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
- Keywords
- IL-18, NLRP3 inflammasome, colorectal cancer, colorectal carcinogenesis, caspase-1, interferon-gamma, STAT1, chronic inflammation, azoxymethane/dextran sulfate sodium, tumor suppression
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Carrier Proteins, Cell Transformation, Neoplastic, Enzyme-Linked Immunosorbent Assay, Inflammation, Mice, Inbred C57BL, Blotting, Western, Colorectal Neoplasms, Cytokines, Mice, Knockout, Reverse Transcriptase Polymerase Chain Reaction, Interleukin-18, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.